Glenmark launches 1st nasal spray for treating adult Covid-19 patients in India
The Mumbai-based pharmaceutical company received manufacturing-marketing approval from India’s drug regulator, Drugs Controller General of India (DCGI) for Nitric Oxide Nasal Spray as part of an accelerated approval process.
Glenmark pharmaceuticals on Wednesday launched a nasal spray in India to treat adult patients suffering from coronavirus disease (Covid-19). Nitric Oxide Nasal Spray named FabiSpray, has been launched in partnership with Canadian pharmaceutical company SaNOtize Research & Development Corp.